<DOC>
	<DOCNO>NCT02658409</DOCNO>
	<brief_summary>A Multicenter , Randomized , Double-blind , Active-controlled , Parallel , Non-inferiority , Phase III Study .</brief_summary>
	<brief_title>A Multicenter , Double-blind , Parallel , Non-inferiority , Phase III Study</brief_title>
	<detailed_description>A Multicenter , Randomized , Double-blind , Active-controlled , Parallel , Non-inferiority , Phase III Study Investigate Efficacy ( Immunogenicity ) Safety GC3106 ( quadrivalent cell-culture base influenza vaccine ) Intramuscular Administration Healthy Subjects .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Given write informed consent Healthy Korean adult ( age : 19 ) Women childbearing age negative Urine hCG screen visit Subjects unable communicate ( illiterate understand questionnaire and/or study subject diary ) Subjects participate another clinical study participate clinical study last 30 day ( participation base final dose investigational drug ) Subjects impaired immune function include immune deficiency diseases Subjects history GuillainBarre syndrome Hemophilia patient risk serious bleed intramuscular injection take anticoagulant Subjects symptom active infection high 38.0â„ƒ fever investigational product administration Subjects plan surgery study duration subject investigator decide exception clinical significant chronic malignant disease medical history interrupt study procedure Subjects erythema and/or tattoo injection site schedule investigational product ( deltoid muscle ) hard identify topical toxicity Subjects history allergic reaction egg chicken , vaccine component , and/or Formaldehyed , Gentamicin Sodium Deoxychloate Subjects administer influenza vaccine 6 month schedule vaccination investigational product Subjects vaccinate another vaccine within 30 day investigational product administration schedule vaccination clinical study period Subjects receive immunosuppressant , immunitymodifying drug , cytotoxic chemotherapy affect immune system , radiation therapy within 3 month investigational product administration Subjects receive systemic steroid ( 20 mg/day prednisolone administer everyday 14 day 700 mg cumulative dose period time ) within 3 month administration ( Day 1 ) investigational product ( topical ointment , eye drop , inhalant intranasally/intramuscularly administer drug , topically apply drug ligament ; unless administer every day 14 day ) Subjects receive immunoglobulin bloodderived product within 3 month vaccinate investigational product schedule receive product clinical study period Pregnant woman , nurse mother , woman childbearing age perform adequate contraception ( use condom , diaphragm , IUD , hormonal contraception 21 day vaccination investigational product whose male partner undergone vasectomy ) Subjects clinically significant medical psychiatric examination finding deem investigator make ineligible participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>CCIV</keyword>
	<keyword>quadrivalent cell-culture base influenza vaccine</keyword>
	<keyword>Influenza vaccine</keyword>
	<keyword>Vaccination</keyword>
</DOC>